Development, manufacturing and characterization of a highly purified, liquid immunoglobulin g preparation from human plasma

Elevated Antibody Titers to Epstein-Barr Virus and Cytomegalovirus in Patients with Drug-Induced Lupus

Systemic lupus erythematosus (SLE) is an autoimmune disease, which has been associated with Epstein-Barr virus (EBV) and Cytomegalovirus (CMV) infection. Drug-induced lupus (DIL) is a lupus-like disease caused by the intake of therapeutic drugs, which has been estimated to cause approximately 10-15% of lupus-like cases. Although SLE and DIL share common clinical symptoms, there are some fundamental differences between DIL and SLE onset. Moreover, it remains to be examined whether environmental factors, such as EBV and CMV infections, may contribute to the development of DIL. This study focused on examining the possible association between DIL and EBV and CMV infections, by examining IgG titers to EBV and CMV antigens in serum samples by enzyme-linked immunosorbent assays. Antibody titers to EBV early antigen-diffuse and CMV pp52 were found to be significantly elevated in both SLE and DIL patients compared to healthy controls, although no correlation was found for antibodies to the two virus antigens in the respective disease groups. Moreover, total IgG titers were reduced in SLE and DIL serum samples, which may reflect a general lymphocytopenia, which commonly is associated with SLE. The current findings support that EBV and CMV infections may contribute to the development of DIL and that onset of both diseases are related.

Coupling of multivariate curve resolution-alternating least squares and mechanistic hard models to investigate antibody purification from human plasma using ion exchange chromatography

A two steps proposal for the purification of immunoglobulin G from human blood plasma is investigated. The first step is precipitation using cold ethanol based on the Cohn method with some modification and the second step is a chromatographic separation by DEAE-Sepharose FF resin as a weak anion exchanger. The presence of interferent in the region3 of chromatographic fractions, which is co-eluted with IgG, restricts the application of the mechanistic chromatography model. Therefore, multivariate cure resolution-alternating least squares (MCR-ALS) as a soft method is employed on measured absorbance data matrix from eluted fractions to recover pure concentration and spectral profiles. Besides, possible solutions for resolved concentration and spectral profiles are investigated. The reaction-dispersive model as a mechanistic hard model for the column is utilized for the evaluation of the ion exchange chromatography. Using a genetic algorithm as a global optimization method, mobile phase modulator (MPM) adsorption model parameters such as β, k_des,0, and K_eq,0, were fitted to the concentration profiles from MCR-ALS as 1.96, 2.87×10^-4 m³ mol^-1s^-1, and 1883, respectively. Furthermore, a new resampling incorporated non-parametric statistics is conducted to assess parameters' uncertainty. Values of 2.00, 1.10×10^-3 m³ mol^-1s^-1, and 549.80 are estimated median, and values of 0.05, 2.5×10^-3, and 691.00 are calculated interquartile range (IQR) for β, k_des,0, and K_eq,0, respectively. Finally, results show three and two outliers for β and k_des,0, respectively.

Therapeutic Antibodies: An Overview

Polyclonal immunoglobulin (Ig) preparations have been used for several decades for treatment of primary and secondary immunodeficiencies and for treatment of some infections and intoxications. This has demonstrated the importance of Igs, also called antibodies (Abs) for prevention and elimination of infections. Moreover, elucidation of the structure and functions of Abs has suggested that they might be useful for targeted treatment of several diseases, including cancers and autoimmune diseases. The development of technologies for production of specific monoclonal Abs (MAbs) in large amounts has led to the production of highly effective therapeutic antibodies (TAbs), a collective term for MAbs (MAbs) with demonstrated clinical efficacy in one or more diseases. The number of approved TAbs is currently around hundred, and an even larger number is under development, including several engineered and modified Ab formats. The use of TAbs has provided new treatment options for many severe diseases, but prediction of clinical effect is difficult, and many patients eventually lose effect, possibly due to development of Abs to the TAbs or to other reasons. The therapeutic efficacy of TAbs can be ascribed to one or more effects, including binding and neutralization of targets, direct cytotoxicity, Ab-dependent complement-dependent cytotoxicity, Ab-dependent cellular cytotoxicity or others. The therapeutic options for TAbs have been expanded by development of several new formats of TAbs, including bispecific Abs, single domain Abs, TAb-drug conjugates, and the use of TAbs for targeted activation of immune cells. Most promisingly, current research and development can be expected to increase the number of clinical conditions, which may benefit from TAbs.

Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy

Background and Objectives

To determine the role of complement in the disease pathology of multifocal motor neuropathy (MMN), we investigated complement activation, and inhibition, on binding of MMN patient-derived immunoglobulin M (IgM) antibodies in an induced pluripotent stem cell (iPSC)-derived motor neuron (MN) model for MMN.

Methods

iPSC-derived MNs were characterized for the expression of complement receptors and membrane-bound regulators, for the binding of circulating IgM anti-GM1 from patients with MMN, and for subsequent fixation of C4 and C3 on incubation with fresh serum. The potency of ARGX-117, a novel inhibitory monoclonal antibody targeting C2, to inhibit fixation of complement was assessed.

Results

iPSC-derived MNs moderately express the complement regulatory proteins CD46 and CD55 and strongly expressed CD59. Furthermore, MNs express C3aR, C5aR, and complement receptor 1. IgM anti-GM1 antibodies in serum from patients with MMN bind to MNs and induce C3 and C4 fixation on incubation with fresh serum. ARGX-117 inhibits complement activation downstream of C4 induced by patient-derived anti-GM1 antibodies bound to MNs.

Discussion

Binding of IgM antibodies from patients with MMN to iPSC-derived MNs induces complement activation. By expressing complement regulatory proteins, particularly CD59, MNs are protected against complement-mediated lysis. Yet, because of expressing C3aR, the function of these cells may be affected by complement activation upstream of membrane attack complex formation. ARGX-117 inhibits complement activation upstream of C3 in this disease model for MMN and therefore represents an intervention strategy to prevent harmful effects of complement in MMN.

Antibodies purification from human plasma using fractionation, chromatography and gel electrophoresis assisted by multivariate analysis of complimentary absorption and fluorescence spectra

Employing simple precipitation (fractionation) using Cohn method and weak anion exchange chromatography with DEAE resin, antibodies such as Immunoglobulin G are purified from human plasma. Fractions are eluted from column in four different regions depending on washing NaCl concentrations. Absorbance and excitation-emission fluorescence spectral data are measured for separated chromatographic fractions and analyzed using Multivariate Curve Resolution- Alternating Least Squares (MCR-ALS) and Parallel Factor Analysis (PARAFAC) techniques. Resolved concentration and spectral profiles provided information about existing components in each fraction. Protein and non-protein components are distinguished considering their resolved pure spectra and information from the two applied spectroscopic techniques is complementary. A number of components displayed both fluorescence and absorbance signals. When concentration of component (protein or non-protein) in sample is low and no significant absorbance signal is observed, sensitive fluorescence is useful to recognize the component and for non-fluorescent components absorbance spectra are utilized. Electrophoresis is utilized for separation of proteins in each fraction and showed that one distinguished protein from fluorescence and/or absorbance data can be a group of proteins with similar pure spectra and retention volume. Results showed presence of two protein in the first region (IgM and IgA), a group of proteins in second region (IgM, α-globulin, and IgG), a pure protein in third region (IgG), and a group of β-globulin proteins in fifth region. It is well and clearly shown that multivariate analysis of different data sets with complementary information is necessary for better interpretation of such technically simple and biochemically complicated systems.

Immunoglobulin G structure and rheumatoid factor epitopes

Antibodies are important for immunity and exist in several classes (IgM, IgD, IgA, IgG, IgE). They are composed of symmetric dimeric molecules with two antigen binding regions (Fab) and a constant part (Fc), usually depicted as Y-shaped molecules. Rheumatoid factors found in patients with rheumatoid arthritis are autoantibodies binding to IgG and paradoxically appear to circulate in blood alongside with their antigen (IgG) without reacting with it. Here, it is shown that rheumatoid factors do not react with native IgG in solution, and that their epitopes only become accessible upon certain physico-chemical treatments (e.g. heat treatment at 57 °C), by physical adsorption on a hydrophobic surface or by antigen binding. Moreover, chemical cross-linking in combination with mass spectrometry showed that the native state of IgG is a compact (closed) form and that the Fab parts of IgG shield the Fc region and thereby control access of rheumatoid factors and presumably also some effector functions. It can be inferred that antibody binding to pathogen surfaces induces a conformational change, which exposes the Fc part with its effector sites and rheumatoid factor epitopes. This has strong implications for understanding antibody structure and physiology and necessitates a conceptual reformulation of IgG models.

Purification of Natural Antibodies Against Tau Protein by Affinity Chromatography

Natural antibodies are now widely studied for their therapeutical potential. Therefore, their isolation and subsequent characterization is desired. Here, we describe an isolation method for natural anti-tau antibodies from human plasma by utilization of affinity chromatography with epoxy-activated copolymer resin. The evalution of isolation efficiency and avidity of isolated antibodies is decribed by modified indirect ELISA assay.